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Abstract
Background: There is ambiguity on how omega‐3 (n‐3) polyunsaturated fatty acids
(PUFAs) are associated with depression, and what the temporality of the association
might be. The present study aimed to examine whether (intervention‐induced
changes in) n‐3 PUFA levels were associated with (changes in) depressive symptoms.
Methods: Baseline, 6‐ and 12‐month follow‐up data on 682 overweight and sub-
clinically depressed persons from four European countries that participated in the
MooDFOOD depression prevention randomized controlled trial were used. Parti-
cipants were allocated to four intervention groups: (a) placebos, (b) placebos and
food‐related behavioral activation therapy (F‐BA), (c) multinutrient supplements
(fish oil and multivitamin), and (d) multinutrient supplements and F‐BA. Depressive
symptoms were measured using the inventory of depressive symptomatology. PUFA
levels (µmol/L) were measured using gas chromatography. Analyses were adjusted
for sociodemographics, lifestyle, and somatic health.
Results: Increases in n‐3 PUFA, docosahexaenoic acid, and eicosapentaenoic acid
levels over time were significantly larger in the supplement groups than in placebo
groups. Change in PUFA levels was not significantly associated with the change in
depressive symptoms (β = .002, SE = 0.003, p = .39; β = .003, SE = 0.005, p = .64;
β = .005, SE = 0.005, p = .29; β = −.0002, SE = 0.0004, p = .69). Baseline PUFA levels
did not modify the intervention effects on depressive symptoms.
Conclusions: In overweight and subclinical depressed persons, multinutrient sup-
plements led to significant increases in n‐3 PUFA levels over time, which were not
associated with changes in depressive symptoms. Multinutrient supplements do not
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seem to be an effective preventive strategy in lowering depressive symptoms over
time in these at‐risk groups.
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1 | INTRODUCTION
Omega‐3 (n‐3) polyunsaturated fatty acids (PUFAs) consist of, for ex-
ample, α‐linolenic acid (ALA), eicosapentaenoic acid (EPA) and doc-
osahexaenoic acid (DHA) and can be mainly found in fatty fish, some
other seafood, and some nuts and seeds (James, Gibson, & Cleland, 2000;
Simopoulos, 1999). ALA is a so‐called essential fatty acid as humans must
ingest ALA through their diet (e.g., leafy green vegetables and in flaxseed
and canola oils), or through supplements as our bodies seem to require
ALA for good health but cannot synthesize ALA by itself (Young &
Conquer, 2005). Omega‐6 (n‐6) PUFAs consist of, for example, linoleic
acid and arachidonic acid, which are, for example, found in plant and
vegetable seeds and oils as found in margarine and many processed foods
(James et al., 2000; Simopoulos, 1999).
Some observational studies have shown that low n‐3 PUFA plasma
levels are more often found in patients with depressive disorders than in
healthy individuals, but other studies do not confirm this (Lin, Huang, &
Su, 2010; Smith, Beilin, & Mori, 2011; Wani, Bhat, & Ara, 2015). Several
potential biochemical mechanisms could explain the association between
PUFAs and depressive disorders (Smith et al., 2011). For a long time, it
was thought that the anti‐inflammatory property of n‐3 PUFAs may
mitigate the overactive immune system associated with several disorders
(Young & Conquer, 2005), whereas n‐6 PUFAs were generally seen as
proinflammatory (Husted & Bouzinova, 2016) because n‐3 and n‐6 PU-
FAs compete for the same substrates. However, it has recently been
discovered that the biochemistry of n‐3 and n‐6 PUFA is much more
nuanced, with both n‐3 and n‐6 PUFAs having proinflammatory and anti‐
inflammatory properties, and neither is “all good” or “all bad” (Nasir &
Bloch, 2019). In addition to inflammatory activities that could underlie
depressive and anxiety disorders, a decrease in dietary DHA is related to
a decrease in cortical serotonin and dopamine (Young & Conquer, 2005),
and these neurotransmitters have been implicated in the etiology of
depressive disorders (Smith et al., 2011; Young & Conquer, 2005). In
addition, fatty acids are implicated as regulators of gene transcription
within the central nervous system (Alessandri et al., 2004; Smith
et al., 2011) and may play a role in neural membrane fluidity and receptor
binding (Owen, Rees, & Parker, 2008; Smith et al., 2011; Stahl, Begg,
Weisinger, & Sinclair, 2008). For instance, DHA can affect neurological
function by modulating neurotransmission, neurogenesis, myelination,
and more (Weiser, Butt, & Mohajeri, 2016). As not all studies have found
this association between low n‐3 PUFA levels and depressive disorders, a
possible role of potential third factors (i.e., residual confounding factors)
has been suggested, such as biological stress (Thesing, Bot, Milaneschi,
Giltay, & Penninx, 2018b) or psychological vulnerabilities (Thesing
et al., 2018a), although these could also be considered mediators.
Despite not all studies finding a cross‐sectional association between
n‐3 PUFAs and depressive disorders, systematic reviews, and meta‐
analysis of the randomized controlled trials (RCTs) that investigated n‐3
PUFA supplementation for the treatment of depressive disorders have
concluded that overall a beneficial effect can be found (Appleton, Rogers,
& Ness, 2010; Appleton, Sallis, Perry, Ness, & Churchill, 2015; Bloch &
Hannestad, 2012; Grosso et al., 2014; Mocking et al., 2016). This seems
especially true for EPA and in patients taking antidepressants, as shown
by a recent meta‐analysis involving 13 studies and 1,233 participants
(Mocking et al., 2016). However, large heterogeneity has been found in
effect sizes, which could possibly be explained by methodological differ-
ences between the studies (e.g., sample backgrounds and supplement
types, doses, and duration). Hence, the clinical significance of the found
effect is still questionable. Some meta‐analytic evidence (Appleton
et al., 2010; Bloch & Hannestad, 2012) suggests a potential role of clinical
depression characteristics in the efficacy of n‐3 PUFA supplementation;
studies including more‐severely depressed patients tend to show higher
efficacy of n‐3 PUFA supplementation to treat depression than studies
including less‐severe‐depressed patients.
It is important to make a distinction between treatment studies and
prevention studies, as the factors involved in the development of a dis-
order in at‐risk individuals may be different than those factors involved in
the course of a depressive disorder in patients. Recently, we showed in
the multicountry MooDFOOD depression prevention trial among 1,025
overweight adults with subclinical depressive symptoms that multi-
nutrient supplementation (including n‐3 PUFA fish oil supplements and a
multivitamin) and a food‐related behavioral activation therapy both did
not reduce the onset of episodes of major depressive disorder during 1
year (Bot et al., 2019). As the supplements contained n‐3 PUFAs and the
food‐related behavioral activation therapy promoted eating fish at least
three times a week, it was hypothesized that both interventions would
lead to an increase in n‐3 PUFA serum levels in participants, which was
hypothesized to lead to a reduction in depressive symptoms and a de-
creased risk for the onset of a new depressive disorder episode. How-
ever, against expectations, the supplements resulted in slightly poorer
depressive and anxiety symptoms scores compared with the placebo.
To date, n‐3 and n‐6 PUFA serum levels are finally available for a
large part of the MooDFOOD sample which provides us with the op-
portunity to examine whether these interventions resulted in a significant
change in n‐3 and n‐6 PUFA levels and whether these changes are re-
lated to a subsequent change in depressive symptoms over time. Fur-
thermore, it could also be that the interventions were only effective in
participants with low baseline n‐3 PUFA levels and high baseline n‐6
PUFA levels, as these subjects may benefit most from the interventions,
also in terms of the impact on depressive symptoms. Consequently, this
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study examined whether both supplementation, as well as food‐related
behavioral activation, lead to an increase in serum PUFA levels and
whether such change is associated with a change in depressive symp-
toms. We also aimed to examine whether participants with lower n‐3
PUFA levels or higher n‐6 PUFA levels at baseline were most responding
to the interventions (e.g., in terms of depression symptoms over time).
2 | METHODS
2.1 | Study design and sample
The MooDFOOD depression prevention trial was designed to measure
the feasibility and effectiveness of two different nutritional strategies to
prevent a new episode of major depressive disorder (MDD) in high‐risk
overweight persons with subclinical symptoms of depression. This study
was a 2× 2 factorial RCT performed between July 30, 2015, and October
13, 2017, in four European countries (Germany, Spain, United Kingdom,
and the Netherlands). For full details of trial design and protocol, see
Roca et al. (2016) and for trial results, see Bot et al. (2019). Ethics ap-
proval was provided by the human research ethics boards of the study
sites. All participants provided written informed consent. A total of 1,025
participants were recruited by the four study sites (located in Leipzig,
Germany; Palma de Mallorca, Spain; Exeter, United Kingdom; and Am-
sterdam, the Netherlands). Main eligibility criteria were: age between 18
and 75 years, body mass index (BMI; calculated as weight in kilograms
divided by height in meters squared) between 25 and 40 kg/m2, and
having at least mild depressive symptoms as operationalized by Patient
Health Questionnaire scores of 5 or higher (Kroenke, Spitzer, & Wil-
liams, 2001) but having no current MDD episode in the past 6 months
(Mini International Neuropsychiatric Interview 5.0; Sheehan et al., 1998).
All eligible participants were invited to visit one of the study sites for a
baseline interview. The interview, physical measurements, and blood
sampling were conducted by trained research assistants or nurses. Fur-
thermore, participants completed self‐report questionnaires. Follow‐up
assessments in which blood was assessed took place at 3, 6, and 12
months. For the analyses of the current study, only participants with
available data on at least one PUFA measurement were included
(N=682). Included participants were significantly older, were physically
more active, drank more glasses of alcohol per week, were more often
higher educated, and were less often current smokers than excluded
participants (n=343). The investigation was carried out in accordance
with the latest version of the Declaration of Helsinki (clinicaltrials.gov;
trial registration number: NCT02529423).
2.2 | Measurements
2.2.1 | Fatty acid measurements
Blood samples were collected at all four sites, stored at −80°C and
shipped to Reference Laboratory in Barcelona (Spain) for analyses using
gas chromatography. For each participant, in total 2ml of blood serum
was used for assessment of n‐3 PUFA, DHA, EPA, and n‐6 PUFA (in
µmol/L). Compared to the other countries, a smaller number of partici-
pants from Germany provided blood samples due to logistic reasons that
were not related to the randomization of the interventions. At baseline,
6 months, and 12 months follow‐up, the number of participants with
available blood data was 673, 479, and 477, respectively.
2.2.2 | Severity of depression
Severity of depressive symptoms was assessed using the 30‐item
self‐report Inventory of Depressive Symptomatology questionnaire
(IDS‐SR30, range 0–84), with higher scores indicating higher severity
(Rush, Gullion, Basco, Jarrett, & Trivedi, 1996). At baseline, 6 months,
and 12 months of follow‐up, the number of participants with avail-
able IDS‐SR30 data was 994, 747, and 757, respectively.
2.2.3 | Intervention groups
Patients received either multinutrient supplements (1,412mg of EPA
and DHA; ratio, 3:1), 30 μg of selenium, 400 μg of folic acid, and 20 μg
of vitamin D3 coupled with 100mg of calcium) provided in two pills
per day taken daily for 1 year, or matching placebo pills. The food‐
related behavioral activation therapy (F‐BA) consisted of a protocol‐
based intervention that incorporated standard behavioral activation
approaches. Behavioral activation is effective in depression treatment
(Ekers et al., 2014) and includes self‐monitoring, functional analysis,
and activity schedule. Food‐related behavioral activation applied these
proven techniques to improve mood by changing dietary habits, food‐
related behaviors (e.g., snacking), increasing positive behaviors, and
emphasizing a Mediterranean‐style diet, which has been related to
reduced depression onset (Molendijk, Molero, Ortuño Sánchez‐
Pedreño, Van der Does, & Angel Martínez‐González, 2018). A max-
imum of 21 sessions was provided (15 individual sessions and 6 in a
group) for 1 year. No active (e.g., attention) control condition was
provided in those receiving no therapy. In total 1,025 participants
were randomized over four intervention groups taking into account
site and history of depressive disorders: (a) placebo without F‐BA
(n = 257), (b) placebo with F‐BA (n = 256), (c) supplement without F‐BA
(n = 256), and (d) supplement with F‐BA (n = 256).
2.2.4 | Covariates
Sociodemographic covariates were age, gender, education, and site
(The Netherlands, Germany, Spain and England). Education was di-
vided into low (no education, primary education, or lower secondary
education), middle (upper secondary education; postsecondary non-
tertiary education, short‐cycle tertiary education), and high (bache-
lor's degree or higher or equivalent level). Somatic health and
lifestyle covariates were BMI (weight in kg/length in m2), physical
activity, smoking (never, former, current), alcohol use, diabetes
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mellitus (yes/no), heart disease (yes/no), number of other chronic
somatic disorders (continuous). As we expected that diagnosis of
diabetes (Mahendran et al., 2013) and heart disease (Würtz
et al., 2015) would have stronger associations with PUFA's, we se-
parated these from other chronic somatic diseases. Physical activity
was measured with the following question from the Short Ques-
tionnaire to Assess Health: “How many days a week do you exercise
(combination of bicycling, gardening, do sport or household work) for
at least 30min?” and expressed in days/week (Wendel‐Vos, Schuit,
Saris, & Kromhout, 2003).
2.3 | Statistical analyses
Frequency and descriptive statistics were used to describe the
baseline sample.
The first analyses examined the association between the four
intervention groups and longitudinal trajectories of n‐3 PUFA, DHA,
EPA, and n‐6 PUFA, for which linear mixed models with a random
intercept at the subject level were used, taking into account the
correlation across repeated measures of the same subject (Twisk
et al., 2018). As compared to traditional repeated measures analyses,
mixed‐effects models have the advantage of making use of the data
of all the subjects despite missing observations. The second analysis
examined whether, over time, change in n‐3 PUFA, DHA, EPA, and n‐
6 PUFA levels was associated with the change in depression severity.
As suggested by Twisk (2013), we used modeling of change scores for
both PUFA levels and depression severity (6‐month follow‐up values
minus baseline values, and 12‐month follow‐up values minus 6‐month
follow‐up values) to create variables reflecting within‐subject change
over the two blocks of time in a long data set. This data set was
analyzed using generalized estimating equation analyses as reported
in Twisk (2013), in which 0‐ to 6‐month change scores in PUFA levels
were used as predictors for 0‐ to 6‐month change scores in depres-
sive symptoms, and 6‐ to 12‐month change scores in PUFA levels
were used as predictors for 6‐ to 12‐month change scores in de-
pressive symptoms. Finally, the third analysis estimated the asso-
ciation between the treatment group (supplements yes/no; F‐BA yes/
no) and depressive symptoms over time, while examining effect
modification by baseline PUFA levels by adding treatment group‐by‐
PUFA baseline levels interaction terms in linear mixed models al-
ready including the related main terms. Analyses were conducted
using IBM SPSS statistics software, version 25 (IBM Corp., Armonk,
NY). Statistical significance threshold was set at α < .05, two‐tailed.
3 | RESULTS
3.1 | Sample description
Descriptive statistics of the study sample are presented in Table 1.
The mean age of all participants included at baseline (N = 682) was
48.6 years (standard deviation = 12.4) and 75.5% were female.
Table S1 shows all Spearman's correlation coefficients between all
PUFA measures at baseline, 6 months, and 12 months of follow‐up.
3.2 | Group differences in PUFA levels over time
Figure 1 depicts the estimated mean n‐3 PUFA, DHA, EPA, and n‐6 PUFA
levels for all four intervention groups derived from a linear mixed model
(Table S2) adjusted for all sociodemographic, lifestyle, and somatic health
covariates. At the 6‐month follow‐up, the supplement group without
F‐BA, and the supplement group with F‐BA, had higher n‐3 PUFA
(Cohen's d=0.27, p< .001; Cohen's d=0.23, p< .001), EPA (Cohen's
d=0.38, p< .001; Cohen's d=0.34, p< .001), and DHA (Cohen's d=0.14,
p= .001; Cohen's d=0.10, p= .013) levels compared to the placebo
without F‐BA group. At the 12‐month follow‐up, the supplement group
without F‐BA and the supplement group with F‐BA, still had higher levels
of n‐3 PUFA (Cohen's d=0.21, p< .001, Cohen's d=0.19, p< .001) and
EPA levels (Cohen's d=0.33, p< .001; Cohen's d=0.31, p< .001) as
compared to the placebo without F‐BA group, but only the supplement
group without F‐BA maintained significantly higher DHA level (d= .09,
p= .032). The placebo group with F‐BA had significantly higher levels of
DHA (d=0.09, p= .033) only at a 6‐month follow‐up, as compared to the
placebo group without F‐BA. No significant differences in mean n‐6 PUFA
levels across the four groups were found at any time point.
3.3 | Longitudinal associations between PUFAs and
depression severity
As shown in Table 2, after adjustment for all sociodemographic,
lifestyle, and somatic health covariates, the changes in n‐3 PUFA,
DHA, EPA, and n‐6 PUFA levels over time were not significantly
associated with changes in depressive symptoms severity (β = .002,
SE = 0.003, p = .39; β = .003, SE = 0.005, p = .64; β = .005, SE = 0.005,
p = .29; β = −.0002, SE = 0.0004, p = .69). These nonsignificant asso-
ciations were consistent between baseline and 6 months of follow‐up
and between 6 and 12 months of follow‐up for all PUFA measures
(PUFA‐by‐time interaction terms: n‐3 PUFA p = .69, DHA p = .89, EPA
p = .53, and n‐6 PUFA p = .81, respectively).
3.4 | Modification of intervention effects on
depressive symptoms by baseline PUFA levels
Table 3 reports the results of mixed models adjusted for all socio-
demographic, lifestyle, and somatic health covariates, examining
whether the effect of multinutrient and n‐3 PUFA fish oil supple-
ments on depressive symptoms over time is modified by baseline n‐3
PUFA, DHA, EPA, and n‐6 PUFA levels. Subjects taking supplements,
as compared to those on placebo, tended to have higher although
statistically not significant, depressive symptoms over the entire
follow‐up (β = 1.13, SE = 0.621, p = .070; β = 1.12, SE = 0.621, p = .070;
β = 1.13, SE = 0.620, p = .068; β = 1.13, SE = 0.622, p = .070,
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TABLE 1 Descriptive statistics of the study sample (n = 682)
Placebo without
F‐BA (n = 164)
Placebo with
F‐BA (n = 175)
Supplement without
F‐BA (n = 174)
Supplement with
F‐BA (n = 169)
Demographic variables
Age, mean (SD) 48.0 (12.1) 48.5 (12.0) 49.2 (13.2) 48.6 (12.2)
Female (%) 72.0 74.9 78.7 76.3
Education (%)
Low 10.4 9.7 14.9 10.7
Middle 42.7 48.0 42.0 40.8
High 47.0 42.3 43.1 48.5
Site of data collection (%)
Germany 6.1 5.7 8.6 8.9
United Kingdom 38.4 34.3 35.6 34.3
Spain 20.7 24.6 21.8 22.5
Netherlands 34.8 35.4 33.9 34.3
Somatic health and lifestyle
BMI, median (p25–75) 30.9 (27.6–33.6) 30.7 (27.8–33.0) 30.8 (28.0–33.0) 30.8 (28.1–33.7)
Diabetes, yes (%) 4.3 4.0 4.6 4.1
Heart disease, yes (%) 4.9 4.6 8.0 6.5
No. of other chronic somatic disordersa,
mean (SD)
0.16 (0.53) 0.22 (0.56) 0.26 (0.73) 0.30 (0.86)
Smoking (%)
Never 42.8 44.0 48.3 43.8
Former 41.5 40.6 38.5 37.9
Current 15.9 15.4 13.2 18.3
Alcohol use (glasses/week), median (p25–75) 1.04 (0.19–3.78) 2.42 (0.19–8.23) 1.04 (0.19–8.23) 1.04 (0.31–3.77)
Physical activity (SQUASH), median (p25–75) 4.00 (2.00–6.00) 4.00 (1.00–5.00) 4.00 (2.00–6.00) 4.00 (2.00–6.75)
Fatty acids
N‐3 PUFA (µmol/L)
Baseline, median (p25–75) 226 (147–283) 209 (131–320) 220 (138–298) 198 (136–298)
6‐month follow‐up, median (p25–75) 210 (158–312) 249 (157–345) 296 (199–410) 290 (186–400)
12‐month follow‐up, median (p25–75) 221 (170–307) 250 (185–317) 297 (211–379) 274 (182–366)
DHA (µmol/L)
Baseline, median (p25–75) 141 (96.0–181) 138 (92.5–204) 145 (92.0–192) 127 (86.0–194)
6‐month follow‐up, median (p25–75) 140 (103–197) 155 (105–220) 163 (114–210) 156 (105–214)
12‐month follow‐up, median (p25–75) 146 (110–198) 160 (118–215) 170 (129–206) 155 (110–207)
EPA (µmol/L)
Baseline, median (p25–75) 75.0 (44.0–111) 73.0 (34.0–112) 77.0 (45.0–109) 74 (42.5–106)
6‐month follow‐up, median (p25–75) 75.0 (52.0–117) 86.0 (54.0–124) 137 (74.0–186) 117 (71.0–192)
12‐month follow‐up, median (p25–75) 77.0 (48.5–109) 81.0 (59.0–112) 122 (78.0–185) 109 (65.5–176)
N‐6 PUFA (µmol/L)
Baseline, median (p25–75) 2,824 (2,427–3,340) 2,793 (2,385–3,265) 2,807 (2,496–3,249) 2,808 (2,386–3,393)
6‐month follow‐up, median (p25–75) 2,724 (2,311–3,379) 2,875 (2,534–3,366) 2,714 (2,337–3,327) 2,722 (2,300–3,199)
12‐month follow‐up, median (p25–75) 2,854 (2,507–3,506) 2,997 (2,576–3,485) 2,763 (2,474–3,141) 2,868 (2,435–3,248)
Depression characteristics
IDS‐SR‐30
Baseline, median (p25–75) 20.0 (14.0–26.0) 21.0 (13.0–29.5) 21.0 (15.0–30.0) 21.0 (15.0–28.0)
6‐month follow‐up, median (p25–75) 12.0 (8.00–20.0) 12.0 (7.00–19.0) 14.0 (8.00–23.0) 15.5 (9.00–21.0)
12‐month follow‐up, median (p25–75) 14.0 (7.00–21.0) 11.0 (6.00–17.5) 12.0 (8.00–21.5) 12.0 (7.00–19.0)
History of MDD, yes (%) 36.0 36.6 39.7 38.5
Abbreviations: AD, antidepressant; BMI, body mass index; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; F‐BA, food‐related behavioral
activation therapy; IDS‐SR‐30, Inventory of depressive symptomatology self‐report questionnaire with 30 questions; MDD, major depressive disorder;
N‐3, omega‐3; N‐6, omega‐6; PUFA, polyunsaturated fatty acids; p, percentile; SD, standard deviation; SQUASH, Short Questionnaire to Assess Health.
aOther than diabetes or heart disease.
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respectively). Baseline n‐3 PUFA, DHA, EPA, and n‐6 PUFA did not
modify the effect of the supplements (p = .40, p = .29, p = .67, and
p = .84, respectively). This was consistent over time (e.g,. all baseline
PUFA‐by‐intervention‐by‐time interaction terms, p > .05). Subjects in
the groups with F‐BA had depressive symptoms severity comparable
to subjects in the groups without F‐BA, and the effect of the F‐BA on
depressive symptoms over time was also not modified by baseline
n‐3 PUFA, DHA, EPA, and n‐6 PUFA levels (results not shown).
4 | DISCUSSION
The present study examined associations of n‐3 PUFA (including DHA
and EPA) and n‐6 PUFA levels with depressive symptoms using data on
682 participants from the MooDFOOD depression prevention trial (Bot
et al., 2019). We found that n‐3 PUFA and EPA levels can be effectively
increased by multinutrient supplements, but these increases were not
associated with a significant reduction in depressive symptoms over time.
Also, baseline PUFA levels did not modify the effect of the multinutrient
supplements or the F‐BA. Therefore, our experimental study does not
support the hypothesis that n‐3 PUFA levels have a direct causal effect
on depressive symptoms.
More specifically, significantly larger increases in n‐3 PUFA and
EPA levels were found in the two supplement groups versus the two
placebo groups, which was consistent with our expectations. This
difference indicates that the n‐3 PUFA supplements were sufficiently
used to give a contrast in blood n‐3 PUFA and EPA levels, as was
already shown in the adherence (77%) to supplements (Bot
et al., 2019). Interestingly, the effect of the supplements tended to
level off at 6 months of follow‐up (see Figure 1), which could mean
that adherence to supplement intake decreased at that time point, or
that there is a ceiling effect, for example, after reaching a certain
level of PUFA you cannot increase PUFA levels any more (Maki,
Palacios, Bell, & Toth, 2017; Meyer & de Groot, 2017). However, a
biological mechanism explaining the specific n‐3 PUFA level at which
a ceiling effect is reached has not been proposed yet. Additionally, it
should be noted that it has not yet been established what the healthy
range is for PUFA levels. As EPA is the main ingredient of these fish
oil supplements (ratio EPA:DHA was 3:1) and as conversion of EPA
into DHA is low (Simopoulos, 1999), it was expected that DHA would
not increase in a similar magnitude, which was confirmed. Perhaps a
higher dosage of DHA would be needed to provide a larger change in
DHA blood levels. Earlier study designs differ in terms of duration
and administration of supplements and in fatty acids measurements
which makes comparing effect sizes difficult. The study by Carney
et al. (2009) has also found a statistical difference in post-
supplementation omega‐3‐index between the supplement group and
placebo group, for which we calculated a Cohen's d of 1.96. In the
present study, for n‐3 PUFA levels after 12 months of supple-
mentation Cohen's ds of 0.27 (supplements without F‐BA group) and
0.19 (supplements with F‐BA group) were found when compared to
the placebo without F‐BA group.
Diet is an important source for n‐3 and n‐6 PUFAs (Simopou-





F IGURE 1 N‐3 PUFA, DHA, EPA, and n‐6 PUFA levels at baseline, 6‐, and 12‐month follow‐up in the group with the placebos and no F‐BA
(n = 164), the group with placebo and F‐BA (n = 175), the group with the supplements without F‐BA (n = 174), and the group with the
supplements and with F‐BA (n = 169; total sample at baseline N = 682). DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; F‐BA,
food‐related behavioral activation therapy; N‐3, omega‐3; N‐6, omega‐6; PUFA, polyunsaturated fatty acids
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(e.g., three times of fish per week), F‐BA did not lead to changes in
PUFA serum levels, as the groups with F‐BA did not have significantly
higher n‐3 PUFA, DHA, or EPA levels or lower n‐6 PUFA levels at
6‐ or 12‐month follow‐up when compared to the groups without
F‐BA, except for higher DHA levels at 6 months of follow‐up in the
group with placebo and F‐BA. The fact that we did not find a con-
sistent increase in all n‐3 PUFA measures and at all time points was
unexpected, because a self‐reported increased intake of food pro-
ducts high in n‐3 PUFAs (e.g., fatty fish, nuts, and seeds) in the F‐BA
groups was found previously in the same MooDFOOD study sample
(Grasso et al., 2019). It seems like the increase of intake of products
high in n‐3 PUFAs was only moderate and therefore may not have led
to substantial increases in all n‐3 PUFAs.
Furthermore, no significant associations were found between
change in n‐3 PUFA, DHA, EPA, and n‐6 PUFA levels with a change in
depressive symptoms. This is in line with a recent study that applied
Mendelian randomization analyses—inferring a causal relationship
TABLE 2 Longitudinal associations between change in n‐3 PUFA,
DHA, EPA, and n‐6 PUFA levels and change in depression
severity (n = 682)
Change in depression severity
β SE p Value
Change in n‐3 PUFA .002 0.003 .39
Time (months)
0–6 (ref.)
6–12 5.27 0.625 <.001
Interaction effects
N‐3 PUFA by 0–6 months (ref.)
N‐3 PUFA by 6–12 months .002 0.005 .69
Change in DHA .003 0.005 .64
Time(months)
0–6 (ref.)
6–12 5.19 0.603 <.001
Interaction effects
DHA by 0–6 months (ref.)
DHA by 6–12 months .001 0.010 .89
Change in EPA .005 0.005 .29
Time (months)
0–6 (ref.)
6–12 5.34 0.638 <.001
Interaction effects
EPA by 0–6 months (ref.)
EPA by 6–12 months .005 0.007 .53
Change n‐6 PUFA −.0002 0.0004 .69
Time (months)
0–6 (ref.)
6–12 5.20 0.599 <.001
Interaction effects
N‐6 PUFA by 0–6 months (ref.)
N‐6 PUFA by 6–12 months −.0002 0.001 .81
Note: Analyses are adjusted for age, gender, site, education, body mass
index, smoking, alcohol use, physical activity, diabetes mellitus, heart
disease, and other chronic somatic disorders.
Abbreviations: DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid;
n‐3, omega‐3; n‐6, omega‐6; PUFA, polyunsaturated fatty acids.
TABLE 3 Longitudinal associations between supplement use and
baseline n‐3 PUFA, DHA, EPA or n‐6 PUFA levels with depression
severity (n = 682)
Depression severity over time
β SE p Value
Baseline n‐3 PUFA .004 0.003 .25
Group
Placebo's (ref.)
Supplement 1.13 0.621 .07
Interactions
n‐3 PUFA‐by‐supplement use −.004 0.005 .40
n‐3 PUFA‐by‐supplement use‐
by‐6 months of follow‐up
.002 0.006 .73
n‐3 PUFA‐by‐supplement use‐
by‐12 months of follow‐up
.006 0.006 .33
Baseline DHA .005 0.005 .36
Group
Placebo's (ref.)
Supplement 1.12 0.621 .070
Interactions





12 months of follow‐up
.008 0.010 .44
Baseline EPA .010 0.007 .199
Group
Placebo's (ref.)
Supplement 1.13 0.620 .068
Interactions





12 months of follow‐up
.016 0.013 .24
Baseline n‐6 PUFA .0001 0.001 .89
Group
Placebo's (ref.)
Supplement 1.13 0.622 .070
Interactions
n‐6 PUFA‐by‐supplement use .0002 0.001 .84
n‐6 PUFA‐by‐supplement use‐
by‐6 months of follow‐up
.001 0.001 .24
n‐6 PUFA‐by‐supplement use‐
by‐12 months of follow‐up
.001 0.001 .27
Note: Analyses are adjusted for age, gender, site, education, body mass
index, smoking, alcohol use, physical activity, diabetes mellitus, heart
disease, and other chronic somatic disorders.
Abbreviations: DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid;
n‐3, omega‐3; n‐6, omega‐6; PUFA, polyunsaturated fatty acids.
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between modifiable risk factors and disease using genetic variants as
a natural experiment—on data from ~500,000 subjects (Milaneschi
et al., 2019). Findings provided no evidence of a causal role of n‐3
PUFA on the risk of MDD onset. The question arises what could be
the nature of the association between n‐3 PUFA levels and depres-
sive disorders. One explanation could be that low n‐3 PUFA levels
may arise when depressive symptoms arise, for example, as an epi-
phenomenon. Possibly, common third factors, such as dysregulations
in biological stress systems (Thesing et al., 2018a) or psychological
vulnerabilities (Thesing et al., 2018a), may lead to both a depressive
disorder and n‐3 PUFA alterations. A second explanation could be
that the direction of the association is the other way around: de-
pressive symptoms may lead, for example, via unhealthy food intake
(e.g., consuming fewer products high in n‐3 PUFAs such as fatty fish),
to lower n‐3 PUFA plasma levels. A third explanation could be that
alterations in PUFA levels are an adaptive process, protecting the
body for future damage by oxidative stress, as some PUFAs are
highly oxidizable (Assies et al., 2014) and as increased levels of oxi-
dative stress have been found in patients with a depressive disorder
(Black, Bot, Scheffer, Cuijpers, & Penninx, 2015). In all three cases,
supplementing persons with n‐3 PUFAs to increase n‐3 PUFA levels
would not be effective in preventing depression, and in the third case,
supplementation may even be harmful (e.g., increase oxidative
stress). It is important to note that in the MooDFOOD prevention
trial the supplements resulted in slightly poorer depressive and an-
xiety symptoms scores compared with placebo (Bot et al., 2019).
Harmful side effects might have been the reason for this.
As stated earlier, it is important to make a distinction between
treatment studies and prevention studies. The three explanations
given above for the possible nature of the association between n‐3
PUFA levels and depressive disorder, are not in line with some meta‐
analyses of RCTs that do find a beneficial treatment effect of n‐3
PUFA supplementation in depressed patients, although with small
effect sizes and, therefore, questionable clinical significance
(Appleton et al., 2010, 2015; Grosso et al., 2014; Mocking
et al., 2016). This suggests that n‐3 PUFA supplements may be less
effective in individuals at risk for depression than in currently de-
pressed patients. Recently, the International Society for Nutritional
Psychiatry Research Practice has formulated guidelines for the use of
n‐3 PUFA supplementation in the treatment and prevention of MDD
(Guu et al., 2019). In response, we argued that there is indeed some
evidence from RCTs for the usefulness of n‐3 PUFA supplementation
in the treatment of clinically depressed cases, but there is not enough
evidence from RCTs on the usefulness of n‐3 PUFA supplementation
in the prevention of depression in at‐risk individuals (Thesing,
Lamers, Bot, Penninx, & Milaneschi, 2019). The question arises how it
can be that n‐3 PUFA supplementation could be effective in the
treatment of clinically depressed patients, but not in the prevention
of depression in subclinically depressed patients, and maybe even
lead to slightly poorer depressive and anxiety symptoms scores
compared with placebo (Bot et al., 2019). One explanation could be
that the biological mechanisms and related markers (including a
chemical imbalance in the brain, e.g., n‐3 PUFA alterations next to
neurotransmitter imbalances) of onset are different from those of
disease progression. Additionally, other markers (such as non-
biological markers, i.e. life events or personality) may be more in-
volved in the onset of a depressive disorder, whereas n‐3 PUFAs
might be involved more in the progression of a depressive disorder. If
this is the case, n‐3 PUFA supplements would be inefficient in pre-
venting the onset of depression, but might be effective in the
treatment of a current depression.
At last, PUFA levels at the start of the study did not modify the
effect of the supplements or the F‐BA on depressive symptoms over
time. It was hypothesized that the interventions would be more ef-
fective in participants with baseline n‐3 PUFA levels in a lower range,
assuming that the multinutrient interventions would improve these
levels, and subsequently impact on depressive symptoms. However,
there was no evidence to suggest this. Careful selection of partici-
pants that might benefit from n‐3 PUFA supplementation (e.g., based
on pretreatment PUFA deficiencies) might therefore not be
indicated.
A strength of the current study is the randomized and double‐
blind 2 × 2 factorial design and the large sample (N = 682) of parti-
cipants that are overweight/obese and have subclinical depressed
symptoms with available data on PUFA levels and depressive
symptoms using a well‐validated instrument (IDS‐SR30). Due to the
preventive nature of this trial, we included participants with elevated
depressive symptoms who did not meet the criteria for MDD at
baseline. The depression symptoms scores at baseline may have been
too low to permit any significant findings, that is, a floor effect. Also,
on average, due to “regression to the mean” phenomenon and the
naturalistic fluctuation of depressive symptoms over time the overall
depressive symptomatology went down in all four intervention
groups over time. In line with this, the onset of MDD was limited
(only 10% developed MDD in our sample), which was lower than
expected and, therefore, the power to analyze this indicator was too
small (see Bot et al., 2019 for more details). One limitation is the
potential generalizability, as we included only participants that were
overweight/obese sample. Baseline blood samples were only avail-
able for 682 (66.5%) of all MooDFOOD participants. Furthermore,
due to drop‐out, only 70% (n = 477) of those with baseline blood
samples had 12‐month follow‐up data. However, we used statistical
methods that allowed us to use the data from all 682 participants at
all time points despite missing observations. Fortunately, included
and excluded participants did not differ on the severity of depression.
Analyses did not further consider food intake, but at baseline, our
intervention groups did not differ (Grasso et al., 2019) on this factor.
As there is no universally agreed/golden standard reference range
for PUFA levels, and as this also depends on measurement aspects
including laboratory‐specific analytical procedures, a reference range
for low versus high PUFA levels cannot be given or used in the
current study.
To summarize, this study shows that n‐3 PUFA and EPA levels
can be effectively increased by fish oil supplements, but that these
observed changes in n‐3 PUFA, EPA, DHA, and n‐6 PUFA levels over
a 6‐month period were not associated with changes in depressive
8 | THESING ET AL.
symptoms in the same period, and that baseline PUFA levels do not
modify the effects of fish oil supplements on depressive symptoms.
This could be one of the many possible explanations for the lack of
preventive effect for depressive disorders found in the MooDFOOD
depression prevention trial study. It can be concluded that the in-
crease in n‐3 PUFA, DHA, and EPA circulating levels obtained
through the n‐3 PUFA supplementation regime implemented in the
MooDFOOD study (Bot et al., 2019) is not associated with a re-
duction in depressive symptoms in persons that have subclinical
depressive symptoms. As several previous RCTs did find a beneficial
treatment effect of n‐3 PUFA supplementation (Appleton et al.,
2010, 2015; Grosso et al., 2014; Mocking et al., 2016), this may mean
that PUFA alterations might be more involved in the progression of a
depressive disorder rather than in the development of a depressive
disorder.
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